INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 265 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $389,000 | -21.9% | 8,357 | -4.1% | 0.15% | -39.4% |
| Q2 2022 | $498,000 | +78.5% | 8,716 | -19.9% | 0.25% | -64.4% |
| Q3 2020 | $279,000 | +27.4% | 10,882 | +7.6% | 0.70% | +636.8% |
| Q3 2018 | $219,000 | -58.9% | 10,109 | -66.5% | 0.10% | -43.8% |
| Q2 2018 | $533,000 | +38.1% | 30,162 | +13.3% | 0.17% | +49.6% |
| Q4 2017 | $386,000 | -1.0% | 26,625 | +7.8% | 0.11% | +2.7% |
| Q3 2017 | $390,000 | +68.8% | 24,700 | +61.4% | 0.11% | -9.1% |
| Q4 2016 | $231,000 | -27.4% | 15,300 | +86.6% | 0.12% | -21.4% |
| Q2 2016 | $318,000 | – | 8,200 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |